MPDL3280A in Patients with Metastatic Bladder Cancer

July 10, 2014
Nicholas J. Vogelzang, MD

Nicholas J. Vogelzang, MD, member of the US Oncology Network, site research leader for Comprehensive Cancer Centers of Nevada, discusses the results of a phase I study that examined the utilization of the anti-PD-L1 antibody MPDL3280A as treatment for patients with metastatic bladder cancer.

Nicholas J. Vogelzang, MD, member of the US Oncology Network, site research leader for Comprehensive Cancer Centers of Nevada, discusses the results of a phase I study that examined the utilization of the anti-PD-L1 antibody MPDL3280A as treatment for patients with metastatic bladder cancer.

Clinical Pearls:

  • MPDL3280A reduced tumors in 43% of patients with previously treated PD-L1-positive metastatic bladder cancer, the study results showed.
  • MPDL3280A was well tolerated during the study.
  • More research needs to be done in order to determine which patients will benefit the most from this treatment.